Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2024-01-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
北京君合（成都）律师事务所关于成都先导药物开发股份有限公司2024年第一次临时股东大会的法律意见书
Regulatory Filings
2024-01-09 Chinese
成都先导药物开发股份有限公司关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It details the company's policies, principles, decision-making authority, pricing principles, approval procedures, and disclosure requirements related to related party transactions. It is a governance document outlining internal rules and procedures rather than a financial report or announcement. There is no indication of financial data, earnings, voting results, or regulatory filings. The content fits the description of Governance Information (CGR), which covers the company's internal rules and governance practices.
2023-12-22 Chinese
成都先导药物开发股份有限公司股东大会议事规则
Governance Information Classification · 100% confidence The document is titled "成都先导药物开发股份有限公司 股东大会议事规则" which translates to "Chengdu Lead Drug Development Co., Ltd. Shareholders' Meeting Rules." It contains detailed rules and procedures governing the conduct of the company's shareholders' meetings, including chapters on the powers of the shareholders' meeting, authorization, meeting system, convening, proposals and notifications, voting and resolutions, meeting records, and other related procedural rules. There is no financial data, earnings information, or report content. Instead, it is a governance document outlining internal rules and procedures for shareholder meetings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-22 Chinese
成都先导药物开发股份有限公司募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, storage, usage, and supervision of funds raised by the company. It references regulatory frameworks such as the Company Law of the People's Republic of China, Securities Law, and Shanghai Stock Exchange rules. The content is a detailed internal policy document on how the company manages raised capital, including procedures for storage, usage, changes in use, and oversight. It does not contain financial statements, earnings data, or audit opinions, nor is it an announcement or presentation. It is a regulatory compliance and internal management document related to capital raised by the company. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, especially internal policies governing such activities. The document length (7875 characters) and detailed procedural content support this classification with high confidence.
2023-12-22 Chinese
成都先导药物开发股份有限公司独立董事工作制度
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and contains detailed governance rules and procedures for independent directors of the company 成都先导药物开发股份有限公司. It includes chapters on qualifications, nomination, rights, duties, and operational procedures of independent directors. There is no financial data, earnings information, or report publication announcement. The content is focused on governance structure and internal rules related to board members, specifically independent directors. This matches the description of Governance Information (CGR) which covers internal rules, board structure, and governance practices. The document length is substantial and contains detailed governance policies, not a brief announcement or a report publication notice.
2023-12-22 Chinese
成都先导药物开发股份有限公司关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 first extraordinary general meeting of shareholders (临时股东大会通知) for Chengdu Lead Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. There is no financial data, earnings, or report content included. The document is an announcement informing shareholders about the meeting and voting process, not the meeting materials or results themselves. The document length is 3494 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting, including notices of meetings.
2023-12-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.